

THESE MEDICINES WERE NOT TESTED BY COMPARING THEM DIRECTLY TO EACH OTHER. THIS INFORMATION IS NOT INTENDED TO BE A COMPARISON OF EFFECTIVENESS OR SAFETY. CURRENT AS OF OCTOBER 2025.

Approved Non-factor Prophylactic Hemophilia Treatments

The chart below may help you and your doctor identify the product attributes that matter to you. Discuss with your doctor to determine treatment options that are right for you.

	HYMPAVZI® (marstacimab-hncq)	Qfitlia® (fitusiran)	Alhemo® (concizumab-mtci)	HEMLIBRA® (emicizumab-kxwh)
Drug class	Anti-TFPI (anti-tissue factor pathway inhibitor) rebalancing therapy	Antithrombin rebalancing therapy	Anti-TFPI (anti-tissue factor pathway inhibitor) rebalancing therapy	Bispecific monoclonal antibody
Approved uses				
Hemophilia type	A and B	A and B	A and B	A only
Inhibitor status	Without inhibitors	With and without inhibitors	With and without inhibitors	With and without inhibitors
Age	12+ years	12+ years	12+ years	All ages
Disease severity	All	All	All	All
Dosing				
	Fixed dose*	Your doctor may adjust your dose based on blood test results (antithrombin levels)	Weight based; dose adjustment required based on drug plasma concentration	Varies based on weight
Loading dose	300 mg on day 1 (two pens)	50 mg every 2 months	1 mg/kg on day 1	3 mg/kg weekly for 4 weeks
Maintenance dose (determined by doctor)	150 mg (one pen) on day 8 and once-weekly thereafter A dose escalation to 300 mg (two pens) may be prescribed	10-50 mg every 1-2 months	0.2 mg/kg daily until individualized dosing is determined (no later than 8 weeks after initiation); individualized dosing ranges from 0.15-0.25 mg/kg daily	1.5 mg/kg every week, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose as prescribed by your healthcare provider.

See next page for more

What is HYMPAVZI?

HYMPAVZI is a prescription medicine used regularly to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old.

IMPORTANT SAFETY INFORMATION

Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI.

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you:

- have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery.
- have a severe short-term (acute) illness such as an infection or injury.
- have been told that you have a risk for blood clots.
- are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.


Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI.
- You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI.
- are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Please see additional Important Safety Information on the next page and see [full Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#), at HYMPAVZI.com

WORK TOGETHER WITH YOUR DOCTOR TO CHOOSE A TREATMENT OPTION THAT BEST FITS YOUR NEEDS.

	HYMPAVZI® (marstacimab-hncq)	Qfitlia® (fitusiran)	Alhemo® (concizumab-mtci)	HEMLIBRA® (emicizumab-kxwh)
Dosing frequency (determined by doctor)	Once weekly	Once every 1 or 2 months	Once daily	Once every 1, 2, or 4 weeks
Treatment-related lab monitoring	No	Yes - antithrombin (AT) levels	Yes - plasma drug concentration	No
Dosage forms and strengths available	150 mg/mL pen	50 mg/0.5 mL pen, 20 mg/0.2 mL vial	60 mg/1.5 mL pen, 150 mg/1.5 mL pen, 300 mg/3 mL pen	30 mg/mL vial, 60 mg/0.4 mL vial, 105 mg/0.7 mL vial, 150 mg/mL vial, 300 mg/2 mL vial
Treatment device	Subcutaneous, prefilled pen	Subcutaneous, prefilled pen	Subcutaneous, prefilled pen	Subcutaneous injection
Needle info	Preattached 27-gauge needle hidden inside needle guard 	- Preattached 27-gauge needle hidden inside needle cover Syringe and vial - Individual single-use needles required and sold separately (27-gauge needle recommended) 	Individual single-use needles required and sold separately (32-gauge needle recommended) 	- Transfer needle (18 gauge) and syringe required to filter from vial - Individual single-use needles required and sold separately (25- to 27-gauge needle recommended) 
Room-temperature storage	Up to 7 days*	Pen: up to 3 months* Vial: until expiration date*	Up to 28 days after first use	Up to 7 days



Ready for a change?

Speak to your doctor about what treatment option may be right for you and download the shared-decision-making guide to support your conversation.

See previous page for more

*Do not return to refrigerator once room temperature is reached.

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HYMPAVZI?

HYMPAVZI may cause serious side effects, including:

- blood clots (thromboembolic events).** HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head which can be life-threatening. Blood clots have happened in people using HYMPAVZI. You may have an increased risk of blood clots if you have certain risk factors. Stop using HYMPAVZI and get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs, redness or discoloration in your arms or legs, shortness of breath, pain in chest or upper back, fast heart rate, cough up blood, feel faint, headache, numbness in your face, eye pain or swelling, trouble seeing
- allergic reactions.** HYMPAVZI may cause allergic reactions, including rash and itching. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness or fainting, fast heartbeat or pounding in your chest, sweating

The most common side effects of HYMPAVZI include: swelling, hardening, redness, bruising, and pain at injection site, headache, and itching

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see additional Important Safety Information on the previous page and see [full Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#), at HYMPAVZI.com

Qfitlia® is a registered trademark of Genzyme Corporation.

Alhemo® is a registered trademark of Novo Nordisk Health Care AG.

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd.

